Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP3 | P42574 | 1/20 | 0.86 |
| ▸ | RAB9A | P51151 | 5/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | NPC1 | O15118 | 5/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.62 |
| ▸ | MAPT | P10636 | 4/20 | 0.62 |
| ▸ | POLB | P06746 | 4/20 | 0.62 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.62 |
| ▸ | TP53 | P04637 | 2/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
| ▸ | MEN1 | O00255 | 3/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.51 |
| ▸ | HTT | P42858 | 2/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32664390 | 0.92 | CASP3 (1.00) | CASP3RAB9AKMT2ANPC1SMN1; SMN2 | |
| SCHEMBL979418 | 0.92 | CASP3 (1.00) | CASP3RAB9AKMT2ANPC1SMN1; SMN2 | |
| SCHEMBL4727131 | 0.83 | KDM4E (0.64) | CASP3RAB9AKMT2ANPC1SMN1; SMN2 | |
| SCHEMBL978553 | 0.82 | CASP3 (0.81) | CASP3RAB9AKMT2ANPC1SMN1; SMN2 | |
| SCHEMBL980586 | 0.81 | CASP3 (0.80) | CASP3RAB9AKMT2ANPC1SMN1; SMN2 | |
| SCHEMBL29350605 | 0.80 | SMN1; SMN2 (0.80) | CASP3RAB9AKMT2ANPC1SMN1; SMN2 | |
| SCHEMBL18216694 | 0.80 | SMN1; SMN2 (0.80) | CASP3RAB9AKMT2ANPC1SMN1; SMN2 | |
| SCHEMBL981812 | 0.80 | MAPT (0.78) | CASP3RAB9AKMT2ANPC1MAPT | |
| SCHEMBL980173 | 0.79 | SMN1; SMN2 (0.77) | CASP3RAB9AKMT2ANPC1SMN1; SMN2 | |
| SCHEMBL982575 | 0.77 | SMN1; SMN2 (1.00) | CASP3RAB9AKMT2ANPC1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021133460-A1 | COMPOSITIONS AND METHODS FOR TREATING CANCER AND IMPROVING EPITHELIAL HOMEOSTASIS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-07-01 | — | — | WO | disclosed |
| US-20110021522-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021522-A1 | ACTIVATORS OF EXECUTIONER PROCASPASES 3, 6 AND 7 | CASP7, CASP3, CASP6 | CASP3 2/4885RAB9A 3095/4885KMT2A 3710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.